NICE chief: NHS faces 'startling costs' from new treatments

Sir Andrew Dillon

The NHS faces a “material challenge” to fund new personalised drugs and deal with the “startling costs” of new medical technology, says the chief executive of the National Institute for Health and Care Excellence.

You need to be an HSJ subscriber to read more


Subscribe to read the full article

With an HSJ subscription you’ll get access to:

  • Expert Briefing newsletters, covering nine topics and regions
  • Weekly Catch Up – a summary of the week’s most important stories
  • Unlimited access to
  • The HSJ app

Enquire about multi-user access